Immunomodulatory progenitor cell therapy (Celixir)

Product Name :
Immunomodulatory progenitor cell therapy (Celixir)

Search keywords :
LY5

drugId :
null

Target Vo:
Leukocyte common antigen

Target Vo Short Name :
L-CA

Moa_Name:
Leukocyte common antigen modulators

First Approval Country :

First Approval Date Filter:
null

Origin Company_Name :
Celixir

Active Company_Name :
Celixir

Active Indication_Name:
Cardiomyopathies

In Active Indication_Name:

Termination Status :

China Termination Status :

Highest Status:
Phase 3 Clinical

China Highest Status:

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
COX2 Mouse mAb Epigenetics
IL-1 alpha Antibody Description
FGFR1 Oncogene Partner Antibody: FGFR1 Oncogene Partner Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 43 kDa, targeting to FGFR1 Oncogene Partner. It can be used for WB,IHC-P assays with tag free, in the background of Human, Mouse, Rat.

Author: Betaine hydrochloride

Related Posts